Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Busy-City
The busy pace continues in NASH as Intercept files an NDA; Galmed moves into Phase III
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip